GLP1R and type 2 diabetes mellitus: Our finding shows that GLP-1 RAs, initially developed for type 2 diabetes and obesity, have shown some promise in reducing alcohol consumption, potentially by targeting the brain’s reward centre, especially in people with body mass index ≥ 30 kg/m2.